Genentech, Inc.
1 DNA Way
South San Francisco
California
94080-4990
United States
Tel: 650-225-1000
Fax: 650-225-6000
Website: http://www.gene.com/
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1204 articles with Genentech, Inc.
-
Amgen and Allergan announced positive top-line results from a Phase I/Phase III trial of their biosimilar candidate, ABP 798, to Genentech and Biogen’s Rituxan (rituximab).
-
The U.S. Food and Drug Administration (FDA) approved South Korea’s Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar to Genentech’s Herceptin (trastuzumab).
-
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
1/17/2019
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq® in combination with Abraxane® and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations.
-
The U.S. government has been pushing to increase access to experimental drugs over the last two years. On August 18, 2018, the RACE for Children Act was signed into law as part of the 2017 FDA Reauthorization Act, which amended the Pediatric Research Equity Act (PREA).
-
PhRMA Welcomes Genentech and Gilead Sciences to Association
1/17/2019
The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Genentech, a member of the Roche Group, South San Francisco, and Gilead Sciences, Inc., Foster City, California joined the association as members.
-
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
-
According to U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, less than two percent of Americans use biologics, but they account for 40 percent of total spending on prescription drugs.
-
With more than 82,500 employees working in the sector, California’s Bay Area is one of the strongest homes for biotech companies in the world.
-
Adaptive Biotechnologies and Genentech Launch Personalized Cancer-Care Program Worth $2 Billion+
1/7/2019
Seattle-based Adaptive Biotechnologies forged a collaboration with Genentech that could be worth up to $2 billion to develop and commercialize novel neoantigen directed T-cell therapies for the individualized treatment of a broad range of cancers. -
Adaptive Biotechnologies to Enter into Worldwide Collaboration and License Agreement with Genentech to Develop Personalized Cellular Therapies for the Treatment of Cancer
1/4/2019
Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech,
-
Traditionally, Genentech has tended to operate with less hands-on scrutiny from the business bean counters at its Swiss Roche headquarters. These more recent job cuts suggest those days may be over.
-
Readers' Picks: Top 10 Stories of 2018
12/28/2018
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more. -
Proteostasis Therapeutics Announces Global License Agreement with Genentech
12/17/2018
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced a worldwide, exclusive license agreement with Genentech, a member of the Roche Group, for rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network.
-
Proteostasis Therapeutics, based in Boston, signed a worldwide, exclusive license deal with Genentech for rights to a possible small molecule modulator within the proteostasis network.
-
Late Thursday, Genentech said the U.S. Food and Drug Administration granted regulatory approval for a combination of Tecentriq and Avastin for treatment of some metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
-
FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
12/6/2018
Approval based on survival benefit of Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy), in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations compared to Avastin plus chemotherapy –
-
Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
12/5/2018
88.3 percent of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0 percent treated with Herceptin, an 11.3 percent improvement
-
FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer
12/5/2018
Genentech today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES-SCLC).
-
New Venclexta® Data Demonstrate Deep Responses in Two of the Most Common Types of Leukemia
12/3/2018
New analyses from the Phase III MURANO study in previously treated chronic lymphocytic leukemia show continued benefit from fixed-duration regimen after a median follow-up of three years
-
Genentech’s Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control in the Largest Pivotal Study to Date of Children With Hemophilia A With Factor VIII Inhibitors
12/3/2018
Nearly 77 percent of children receiving Hemlibra once weekly experienced zero treated bleeds